Anderson, K C

Dimopoulos, M

Eid, J

Gause, C

Graef, T

Houp, J

Mitsiades, C

Moreau, P

Richardson, P

Siegel, D S

Vuocolo, S

Weber, D

Blood Cancer Journal

Harvard University - DASH 

 Vorinostat in combination with lenalidomide and dexamethasonein patients with relapsed or refractory multiple myeloma  (Article begins on next page)The Harvard community has made this article openly available.Please share how this access benefits you. Your story matters.Citation Siegel, D. S., P. Richardson, M. Dimopoulos, P. Moreau, C.Mitsiades, D. Weber, J. Houp, et al. 2014. “Vorinostat incombination with lenalidomide and dexamethasone in patientswith relapsed or refractory multiple myeloma.” Blood CancerJournal 4 (4): e202. doi:10.1038/bcj.2014.23.http://dx.doi.org/10.1038/bcj.2014.23.Published Version doi:10.1038/bcj.2014.23Accessed February 19, 2015 4:01:07 PM ESTCitable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12153006Terms of Use This article was downloaded from Harvard University's DASHrepository, and is made available under the terms and conditionsapplicable to Other Posted Material, as set forth athttp://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACORRIGENDUMVorinostat in combination with lenalidomide and dexamethasonein patients with relapsed or refractory multiple myelomaDS Siegel1,9,10, P Richardson2,9, M Dimopoulos3, P Moreau4, C Mitsiades1, D Weber5, J Houp6, C Gause6, S Vuocolo6, J Eid6,T Graef7 and KC Anderson8Blood Cancer Journal (2014) 4, e202; doi:10.1038/bcj.2014.23; published online 11 April 2014Correction to: Blood Cancer Journal (2014) 4, e182; doi:10.1038/bcj.2014.1; published online 21 February 2014Since the publication of this article, the authors have identiﬁed anerror concerning one of the author afﬁliation addresses. KCAnderson was incorrectly afﬁliated to the following address:‘Merck & Co. Inc., Whitehouse Station, NJ, USA’. The correctaddress details are shown here.The article has also been rectiﬁed, and now carries the correctinformation.The Authors would like to apologise for any inconvenience thismay have caused.1Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA;2Dana-Farber Cancer Institute, Boston, MA, USA;3Department of ClinicalTherapeutics, University of Athens, Athens, Greece;4University Hospital, Nantes, France;5MD Anderson Cancer Center, Houston, TX, USA;6Merck & Co. Inc., Whitehouse Station, NJ,USA;7Pharmacyclics Inc., Sunnyvale, CA, USA and8Department of Medicine, Harvard Medical School and Kraft Family Blood Center, Dana-Farber Cancer Institute, Boston, MA, USA.Correspondence: Dr DS Siegel, Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA.E-mail: DSiegel@HackensackUMC.org9These authors contributed equally to this work.10As corresponding author, Dr Siegel assumes full responsibility for the overall content and integrity of the manuscript.Citation: Blood Cancer Journal (2014) 4, e202; doi:10.1038/bcj.2014.23& 2014 Macmillan Publishers Limited All rights reserved 2044-5385/14www.nature.com/bcj

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

http://dash.harvard.edu/bitstream/handle/1/12153006/4003417.pdf?sequence=1

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

Abstract

Similar works

Full text

Available Versions

Harvard University - DASH